natgillin/translations-raw huggingface dataset:
After one week the dose may be titrated, on an individual basis, to achieve the lowest effective dose required to reduce and/or maintain a platelet count below 600 x 109/l and ideally at levels between 150 x 109/l and 400 x 109/l.
Nakon jednog tjedna dozu se može titrirati u svakog bolesnika pojedinačno, kako bi se postigla najniža učinkovita doza koja je potrebna da se broj trombocita smanji i/ili održi ispod 600 x 109/l, a idealno na razinama između 150 x 109/l i 400 x 109/l.
After one year
Nakon jedne godine
After one year (primary endpoint)
Nakon jedne godine (primarni ishod)
After one year of treatment, injections may be given less frequently depending on the response to treatment.
Nakon jedne godine liječenja, injekcije se mogu davati rjeđe ovisno o odgovoru na liječenje.
After opening do not store above 25°C. Keep the container tightly closed in order to protect from light and moisture.
Nakon otvaranja ne čuvati na temperaturi iznad 25°C. Spremnik čuvati čvrsto zatvoren radi zaštite od svjetlosti i vlage.
After opening of the aluminium pouches, the single-dose containers should be kept in the pouches in order to protect from light and avoid evaporation.
Nakon otvaranja aluminijske vrećice jednodozne spremnike treba i dalje čuvati u vrećici radi zaštite od svjetlosti i izbjegavanja isparavanja.
After opening of the vial
Nakon otvaranja
After opening the ampoule, the medicinal product should be used immediately.
Nakon otvaranja ampule, lijek se mora odmah primijeniti.
After opening the bag, the product should be used immediately in order to avoid microbial contamination.
Nakon otvaranja vrećice, lijek treba odmah primijeniti kako bi se izbjeglo mikrobiološko onečišćenje.
After opening the blister pouch, use within 60 days.
Nakon otvaranja blister pakiranja, upotrijebiti unutar 60 dana.
After opening the blister pouch, use within 60 days.
Nakon otvaranja blister vrećice, upotrijebiti unutar 60 dana.
After opening the blister: The orodispersible tablet is moisture sensitive so should be taken immediately after opening the blister.
Nakon otvaranja blistera: raspadljiva tableta za usta osjetljiva je na vlagu pa je treba uzeti odmah čim se otvori blister.
After opening the bottle, chemical and physical in-use stability has been demonstrated for 24 hours at 2 to 8ºC and 25ºC. From a microbiological point of view, the product should be used immediately.
Nakon otvaranja bočice, dokazana je kemijska i fizikalna stabilnost u primjeni tijekom 24 sata na temperaturi od 2 do 8°C te na 25ºC. S mikrobiološkog stajališta, lijek treba odmah primijeniti.
After opening the bottle, the product should be used immediately in order to avoid microbial contamination.
Nakon otvaranja bočice, lijek treba odmah primijeniti kako bi se izbjeglo mikrobiološko onečišćenje.
After opening the bottle, use within 60 days.
Nakon otvaranja boce, upotrijebite unutar 60 dana.
After opening the bottle, use within 60 days.
Nakon otvaranja bočice upotrijebiti u roku od 60 dana.
After opening the drops should be used within 8 weeks.
Nakon otvaranja upotrijebiti unutar 8 tjedana.
After opening the vial, chemical and physical in-use stability of idarucizumab has been demonstrated for 1 hour at room temperature.
Nakon otvaranja bočice, kemijska i fizikalna stabilnost idarucizumaba tijekom uporabe pokazana je za 1 sat na sobnoj temperaturi.
After opening the vial, the product should be used immediately (within 1 hour maximum).
Nakon otvaranja bočice, lijek se mora primijeniti odmah (najviše unutar 1 sata).
After opening, the medicinal product should be used immediately.
Nakon otvaranja lijek treba odmah primijeniti.
After opening, the solution can be used up to the expiry date on the bottle.
Nakon otvaranja: otopina se može primjenjivati do isteka roka valjanosti navedenog na boci.
After opening: 1 year
Nakon otvaranja: 1 godina
After opening: 24 hours at 2oC – 8oC.
Nakon otvaranja: 24 sata na 2oC – 8oC.
After opening: 24 hours at 2°C - 8°C
Nakon otvaranja: 24 sata pri 2°C - 8°C
After opening: 24 hours at 2°C - 8°C.
Nakon otvaranja: 24 sata na 2°C - 8°C.
After opening: do not store above 25ºC.
Nakon otvaranja: ne čuvati na temperaturi iznad 25 ºC.
After opening: Do not store above 25C.
Nakon otvaranja: ne čuvati na temperaturi iznad 25 C.
After opening: the solution should be used within 45 days.
Nakon otvaranja otopinu je potrebno iskoristiti u roku od 45 dana.
After opening: use product immediately.
Nakon otvaranja: lijek upotrijebiti odmah.
After oral administration in fed conditions, peak plasma concentrations of dronedarone and the main circulating active metabolite (N-debutyl metabolite) are reached within 3 to 6 hours.
Nakon peroralne primjene uz obrok vršne koncentracije dronedarona i glavnog aktivnog cirkulirajućeg metabolita (N-debutil metabolit) u plazmi postižu se za 3 do 6 sati.
After oral administration of 10 mg caffeine base/kg body weight to preterm newborn infants, the peak plasma caffeine concentration (Cmax) ranged from 6 to 10 mg/l and the mean time to reach peak concentration (tmax) ranged from 30 min to 2 h.
Nakon peroralne primjene 10 mg kofeina u obliku baze /kg tjelesne težine u nedonoščadi, raspon vršnih koncentracija kofeina u plazmi (Cmax) bio je između 6 i 10 mg/l, a prosječno vrijeme do postizanja vršne koncentracije (tmax) kretalo se u rasponu od 30 min do 2 h.
After oral administration of 14C-labelled TMZ, mean faecal excretion of 14C over 7 days post-dose was 0.8 % indicating complete absorption.
Nakon peroralne primjene temozolomida označenog radioizotopom 14C, u fecesu je tijekom 7 dana nakon primjene doze izlučeno prosječno 0,8 % radioizotopa 14C, što ukazuje na potpunu apsorpciju.
After oral administration of 14C-labelled TMZ, mean faecal excretion of 14C over 7 days post-dose was 0.8% indicating complete absorption.
Nakon peroralne primjene temozolomida označenog radioizotopom 14C, u fecesu je tijekom 7 dana nakon primjene doze izlučeno prosječno 0,8% radioizotopa 14C, što ukazuje na potpunu apsorpciju.
After oral administration of 14C-labelled TMZ, mean faecal excretion of 14C over 7 days post-dose was 0.8% indicating complete absorption.
Nakon peroralne primjene temozolomida označenog radioizotopom 14C, u fecesu je tijekom 7 dana nakon primjene doze izlučeno prosječno 0,8% radioizotopa 14C, što upućuje na potpunu apsorpciju.
After oral administration of 14C-nepafenac to healthy volunteers, urinary excretion was found to be the major route of radioactive excretions, accounting for approximately 85% while faecal excretion represented approximately 6% of the dose.
Nakon peroralne primjene 14C-nepafenaka u zdravih dobrovoljaca, utvrđeno je da je izlučivanje mokraćom glavni put izlučivanja radioaktivno obilježenog lijeka, na što otpada oko 85% doze, dok se sa stolicom izlučuje oko 6% doze.
After oral administration of 150 mg every 12 hours for 7 days in healthy volunteers in a fed state, the mean (±SD) apparent volume of distribution was 353 (122) L.
Nakon peroralne primjene 150 mg svakih 12 sati tijekom 7 dana zdravim dobrovoljcima u sitom stanju, srednji (±SD) prividni volumen distribucije iznosio je 353 (122) l.
After oral administration of 20 mg/kg of hydroxycarbamide, a rapid absorption is observed with peak plasma levels of about 30 mg/l occurring after 0.75 and 1.2 h in children and adult patients with Sickle Cell Syndrome, respectively.
Nakon peroralnog uzimanja 20 mg/kg hidroksikarbamida, zabilježena je brza apsorpcija s vršnim vrijednostima u plazmi od oko 30 mg/l koja je nastupila nakon 45 minuta kod djece i 72 minute kod odraslih bolesnika sa sindromom srpastih stanica.
After oral administration of a single 150 mg dose to healthy volunteers in a fed state, the mean (±SD) for AUC and Cmax were 10600 (5260) ng*hr/mL and 768 (233) ng/mL, respectively.
Nakon peroralne primjene jednokratne doze od 150 mg zdravim ispitanicima nakon obroka, srednja vrijednost (±SD) AUC bila je 10 600 (5260) ng*h/ml, a Cmax 768 (233) ng/ml.
After oral administration of cinacalcet, maximum plasma cinacalcet concentration is achieved in approximately 2 to 6 hours.
Nakon oralne primjene sinakalceta, maksimalna koncentracija sinakalceta u plazmi postiže se nakon otprilike 2 do 6 sati.
After oral administration of emtricitabine or tenofovir disoproxil fumarate, emtricitabine and tenofovir are widely distributed throughout the body.
Nakon peroralne primjene emtricitabina ili tenofovirdizoproksilfumarata, emtricitabin i tenofovir se široko distribuiraju po tijelu.
After oral administration of emtricitabine or tenofovir disoproxil fumarate, emtricitabine and tenofovir are widely distributed throughout the body.
Nakon peroralne primjene emtricitabina illi tenofovirdizoproksilfumarata, emtricitabin i tenofovir se široko distribuiraju po tijelu.
After oral administration of fesoterodine, approximately 70% of the administered dose was recovered in urine as the active metabolite (16%), carboxy metabolite (34%), carboxy-N-desisopropyl metabolite (18%), or N-desisopropyl metabolite (1%), and a smaller amount (7%) was recovered in faeces.
Nakon peroralne primjene fesoterodina, približno se 70% primijenjene doze otkrije u mokraći u obliku djelatnog metabolita (16%), karboksi metabolita (34%), karboksi-N-dezizopropilnog metabolita (18%) ili N-dezizopropilnog metabolita (1%), a manja je količina (7%) otkrivena u stolici.
After oral administration of ivacaftor 250 mg every 12 hours in combination with lumacaftor, the typical apparent volumes of distribution for the central and peripheral compartments (CV) were estimated to be 95.0 L (53.9%) and 201 L (26.6%), respectively.
Nakon peroralne primjene ivakaftora u dozi od 250 mg svakih 12 sati u kombinaciji s lumakaftorom, procijenjeni tipični prividni volumen distribucije (CV) za središnji odjeljak bio je 95,0 L (53,9%), a za periferni odjeljak 201 L (26,6%).
After oral administration of ivacaftor alone as 150 mg q12h in a fed state, the steady-state mean (±SD) for AUC0-12h and Cmax were 9.08 (3.20) g∙hr/mL and 1.12 (0.319) g/mL, respectively.
Nakon peroralne primjene samo ivakaftora u dozi od 150 mg svakih 12 sati u stanju sitosti, srednje vrijednosti (±SD) u stanju dinamičke ravnoteže za AUC0-12h i Cmax bile su 9,08 (3,20) g∙hr/mL odnosno 1,12 (0,319) g/mL.
After oral administration of Lonsurf with [14C]-tipiracil hydrochloride, at least 27% of the administered tipiracil hydrochloride was absorbed and 50% of the total radioactivity dose measured into faeces, suggestive of moderate gastrointestinal absorption of tipiracil hydrochloride.
Nakon peroralne primjene Lonsurfa s [14C]- tipiracilkloridom, najmanje je 27% primjenjenog tipiracilklorida apsorbirano i 50% ukupne radioaktivno obilježene doze određeno u fecesu, što upućuje na umjerenu gastrointestinalnu apsorpciju tipiracilklorida.
After oral administration of Mimpara, maximum plasma cinacalcet concentration is achieved in approximately 2 to 6 hours.
Nakon oralne primjene Mimpare, maksimalna koncentracija sinakalceta u plazmi postiže se nakon otprilike 2 do 6 sati.
After oral administration of Pradaxa in healthy volunteers, the pharmacokinetic profile of dabigatran in plasma is characterized by a rapid increase in plasma concentrations with Cmax attained within 0.5 and 2.0 hours post administration.
Nakon peroralne primjene Pradaxe u zdravih dobrovoljaca, farmakokinetički profil dabigatrana u plazmi karakteriziran je naglim povećanjem koncetracija u plazmi s Cmax postignutim u roku 0,5 i 2,0 sata nakon primjene.
After oral administration of Ranexa, peak plasma concentrations (Cmax) are typically observed between 2 and 6 hours.
Nakon peroralne primjene Ranexe, vršne koncentracije u plazmi (Cmax) uobičajeno se bilježe nakon 2 i 6 sati.
After oral administration of robenacoxib flavoured tablets at 1 mg/kg without food, peak blood concentrations are attained rapidly with a Tmax of 0.5 h, a Cmax of 1,124 ng/ml and an AUC of
Nakon peroralne primjene tableta robenakoksiba s umjetnim okusom u dozama od 1 mg/kg bez hrane, vršne koncentracije u krvi postignute su brzo, s Tmax od 0,5 sati, Cmax od 1124 ng/ml i AUC od 1249 ng·h/ml.
After oral administration of robenacoxib tablets at approximately 2 mg/kg without food, peak blood concentrations are attained rapidly with a Tmax of 0.5 h, a Cmax of 1,159 ng/ml and an AUC of 1,337 ng·h/ml.
Nakon peroralne primjene tableta robenakoksiba u dozama od približno 2 mg/kg bez hrane, vršne koncentracije u krvi postignute su ubrzano s Tmax od 0,5 sati, Cmax od 1159 ng/ml i AUC od 1337 ng·h/ml.
After oral administration of sunitinib, maximum concentrations (Cmax) are generally observed from 6 to 12 hours (tmax) post-administration.
Nakon peroralne primjene sunitiniba vršne se koncentracije (Cmax) u pravilu bilježe u roku od 6-12 sati (tmax) nakon uzimanja.
After oral administration of tenofovir disoproxil fumarate, tenofovir is distributed to most tissues with the highest concentrations occurring in the kidney, liver and the intestinal contents (preclinical studies).
Nakon peroralne primjene tenofovirdizoproksilfumarata tenofovir se raspodjeljuje u većinu tkiva, kod čega su najviše koncentracije u bubregu, jetri i sadržaju crijeva (neklinička ispitivanja).
After oral administration of the single components emtricitabine and tenofovir disoproxil fumarate, emtricitabine and tenofovir are widely distributed throughout the body.
Nakon peroralne primjene emtricitabina i tenofovirdizoproksilfumarata kao pojedinačnih komponenti, emtricitabin i tenofovir široko se distribuiraju po cijelom tijelu.
After oral administration of therapeutic doses of amlodipine alone, peak plasma concentrations of amlodipine are reached in 6-12 hours.
Nakon peroralne primjene terapijskih doza samog amlodipina, vršne koncentracije amlodipina u plazmi postižu se za 6–12 sati.
After oral administration the elimination becomes absorption rate limited.
Nakon peroralne primjene, eliminacija postaje ograničena brzinom apsorpcije.
After oral administration to adult patients, TMZ is absorbed rapidly with peak concentrations reached as early as 20 minutes post administration (mean times between 0.5 and 1.5 hours).
Nakon peroralne primjene u odraslih bolesnika TMZ se brzo apsorbira te postiže vršne koncentracije već 20 minuta nakon primjene (prosječno vrijeme između 0,5 i 1,5 sati).
After oral administration, desloratadine selectively blocks peripheral histamine H1- receptors because the substance is excluded from entry to the central nervous system.
Nakon peroralne primjene, desloratadin selektivno blokira periferne histaminske H1-receptore budući da ne prodire u središnji živčani sustav.
After oral administration, metformin absorption is saturable and incomplete.
Nakon peroralne primjene može doći do zasićenja i nepotpune apsorpcije metformina.
After oral administration, telmisartan is almost exclusively excreted with faeces mainly as unchanged compound.
Nakon peroralne primjene telmisartan se gotovo isključivo izlučuje putem stolice, uglavnom kao nepromijenjeni spoj.
After oral administration, the majority of the administered dose is excreted in urine (41.8%) and faeces (51.4%), mainly as metabolites.
Nakon peroralne primjene, većina primijenjene doze izlučuje se mokraćom (41,8%) i stolicom (51,4%), uglavnom u obliku metabolita.
After oral administration, the systemic exposure is proportional to dose up to 500 mg.
Nakon oralne primjene sistemska izloženost je proporcionalna sve do doze od 500 mg.
After oral and intravenous administration of radiolabeled lacosamide, approximately 95% of radioactivity administered was recovered in the urine and less than 0.5% in the feces.
Nakon peroralne i intravenske primjene radioaktivno označenog lakozamida u mokraći je nađeno oko 95% primijenjene radioaktivnosti, a u fecesu manje od 0,5%.
After oral doses of 80 mg three times a day a more than dose proportional increase in sildenafil plasma levels has been observed.
Nakon peroralne primjene doze od 80 mg tri puta na dan opažen je porast koncentracije sildenafila u plazmi veći od proporcionalnog dozi.
After oral dosing of vardenafil AUC and Cmax increase almost dose proportionally over the recommended dose range (5 – 20 mg).
Nakon peroralne primjene, AUC i Cmax vardenafila povećavaju se gotovo proporcionalno primijenjenoj dozi unutar raspona preporučenih doza (5-20 mg).
After oral dosing of vardenafil AUC and Cmax increase almost dose proportionally over the recommended dose range (5-20 mg).
Nakon peroralne primjene, AUC i Cmax vardenafila povećavaju se gotovo proporcionalno primijenjenoj dozi unutar raspona preporučenih doza (5-20 mg).
After oral three times a day dosing of sildenafil, AUC and Cmax increase in proportion with dose over the dose range of 20-40 mg.
Nakon peroralne primjene sildenafila tri puta na dan, AUC i Cmax povećavaju se razmjerno dozi u rasponu doza od 20-40 mg.
After oromucosal administration midazolam is absorbed rapidly.
Nakon primjene kroz oralnu sluznicu midazolam se brzo apsorbira.
After patient tolerance is established, the infusion rate may be increased gradually with subsequent infusions.
Nakon što se utvrdi da bolesnik dobro podnosi infuziju, njezina brzina može se u sljedećim infuzijama postupno povećavati.
After preparation each ml contains 10 mg of infliximab
Nakon pripreme otopine, jedan ml sadrži 10 mg infliksimaba.
After preparation each mL contains 10 mg of infliximab.
Nakon pripreme otopine, jedan ml sadrži 10 mg infliksimaba.
After preparation of the final solution for injection, there are 75 IU (5.5 micrograms) of follitropin alfa in each millilitre of solution.
Nakon pripreme završne otopine za injekciju u svakom se mililitru otopine nalazi 75 IU (5,5 mikrograma) folitropina alfa.
After preparation, the solution for subcutaneous injection can be used immediately or can be stored at 2°C to 8°C for up to 24 hours.
Nakon pripreme, otopina za potkožnu injekciju može se odmah primijeniti ili se može pohraniti na temperaturi od 2°C do 8°C do 24 sata.
After preparation, the suspension should be administered immediately.
Nakon pripreme, suspenzija se mora odmah primijeniti.
After preparation, the suspension should be administered immediately.
Nakon pripreme, suspenziju treba odmah primijeniti.
After preparation, the suspension should be taken immediately.
Suspenzija se mora uzeti odmah nakon pripreme.
After preparing the Enbrel solution, immediate use is recommended (up to a maximum of 6 hours).
Nakon pripreme otopine Enbrela preporučuje se odmah je primijeniti (u roku od najviše 6 sati).
After preparing the Enbrel solution, immediate use is recommended.
Nakon pripreme otopine Enbrela, preporučuje se odmah je primijeniti.
After preparing the Enbrel solution, immediate use is recommended.
Nakon pripreme preporuča se odmah primijeniti otopinu Enbrela.
After preparing the Enbrel solution, immediate use is recommended.
Nakon pripreme preporučuje se odmah primijeniti otopinu Enbrela.
After preparing the Enbrel solution, immediate use is recommended.
Nakon pripreme, preporuča se odmah primijeniti otopinu Enbrela.
After priming, use within 5 days.
Upotrijebiti u roku od 5 dana od aktivacije.
After priming, use within 5 days.
Upotrijebiti u roku od 5 dana od aktiviranja.
After proper training in injection technique, patients may self-inject using the pre-filled pen if their physician determines that it is appropriate and with medical follow-up as necessary.
Bolesnici mogu sami injicirati lijek nakon odgovarajuće vježbe tehnike injiciranja primjenjujući napunjenu brizgalicu, ako njihov liječnik procijeni da je to prihvatljivo, i prema potrebi uz liječničko praćenje.
After proper training in injection technique, patients may self-inject using the pre-filled syringe if their physician determines that it is appropriate and with medical follow-up as necessary.
Bolesnici mogu sami injicirati lijek nakon odgovarajuće vježbe tehnike injiciranja primjenjujući napunjenu štrcaljku, ako njihov liječnik procijeni da je to prihvatljivo, i prema potrebi uz liječničko praćenje.
After proper training in injection technique, patients may self-inject with Humira if their physician determines that it is appropriate and with medical follow-up as necessary.
Nakon odgovarajuće poduke o tehnici ubrizgavanja injekcija, bolesnici mogu sami sebi davati injekcije lijeka Humira ako njihov liječnik procijeni da je to moguće provesti, uz medicinsko praćenje po potrebi.
After proper training in subcutaneous injection technique, patients may self-inject Taltz if a healthcare professional determines that it is appropriate.
Nakon propisne obuke o tehnici supkutanog injiciranja, bolesnici mogu sami injicirati Taltz ako zdravstveni radnik utvrdi da je to prikladno.
After proper training in subcutaneous injection technique, patients may self-inject with Simponi if their physician determines that this is appropriate, with medical follow-up as necessary.
Nakon odgovarajuće poduke u tehnici davanja supkutane injekcije bolesnici mogu sami sebi injicirati Simponi ukoliko njihov liječnik utvrdi da je to prikladno, uz liječničku kontrolu po potrebi.
After proper training, the injection can be given by yourself or given by another person, for example, a family member or friend.
Nakon primjerene obuke, injekciju si možete dati sami, ili Vam je može dati druga osoba, primjerice član obitelji ili prijatelj.
After proper training, the injection can be self-administered or given by another person, for example a family member or friend.
Nakon primjerene obuke, injekciju si možete dati sami ili Vam je može dati druga osoba, primjerice član obitelji ili prijatelj.
After proper training, the injection can be self-administered or given by another person, for example a family member or friend.
Nakon primjerene obuke, injekciju si možete dati sami, ili Vam je može dati druga osoba, primjerice član obitelji ili prijatelj.
After radiolabelling with sodium pertechnetate ( Tc) solution, the technetium ( Tc) besilesomab solution obtained is indicated in adults for scintigraphic imaging, in conjunction with other appropriate imaging modalities, for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis.
Nakon radioaktivnog obilježavanja s otopinom natrijevog pertehnetata (99mTc), dobivena otopina tehnecijevog (99mTc) besilesomaba indicirana je u odraslih za scintigrafsko oslikavanje, zajedno s drugim odgovarajućim metodama slikovne dijagnostike, radi utvrđivanja lokacije upale/infekcije u perifernim kostima kod odraslih osoba kod kojih postoji sumnja na osteomijelitis.
After radiolabelling, immediate use is recommended.
Nakon radioaktivnog označavanja preporučuje se trenutna primjena.
After randomized withdrawal from therapy at Week 32, approximately 70% of patients in Study ESTEEM 1, and 65.6% of patients in Study ESTEEM 2, regained PASI-75 (ESTEEM 1) or PASI-50 (ESTEEM 2) responses after re-initiation of apremilast treatment.
Nakon obustave randomiziranog liječenja u 32. tjednu, približno 70% bolesnika u ispitivanju ESTEEM 1 i 65,6% bolesnika u ispitivanju ESTEEM 2 vratilo se na odgovore PASI-75 (ESTEEM 1) ili PASI-50 (ESTEEM 2) poslije ponovnog uvođenja terapije apremilastom.
After reaching peak concentration, plasma disposition of telbivudine declined in an bi-exponential manner with a terminal elimination half-life (t1/2) of 41.8 ± 11.8 hours.
Nakon postizanja vršne koncentracije, raspoloživost telbivudina u plazmi smanjivala se po bi-eksponencijalnom obrascu, s terminalnim poluvremenom eliminacije (t1/2) od 41,8 ± 11,8 sati.
After reaching peak levels, entecavir plasma concentrations decreased in a bi- exponential manner with a terminal elimination half-life of  128-149 hours.
Nakon što je postigla vršne razine, koncentracija entekavira u plazmi smanjivala se na bieksponencijalni način s terminalnim poluvijekom eliminacije od  128-149 sati.
After receiving Flebogamma DIF, the results of certain blood tests (serological tests) may be interfered for a certain time.
Nakon primjene, Flebogamma DIF može neko vrijeme utjecati na rezultate nekih krvnih pretraga (seroloških testova).
After receiving Hizentra, the results of certain blood tests (serological tests) may be impaired for a certain time.
Nakon primanja Hizentre, vrijednosti rezultata nekih krvnih pretraga (seroloških testova) mogu biti umanjene na određeno vrijeme.
After reconsititution use within 3 hours.
Upotrijebiti unutar 3 sata od pripreme.